Annual Conference & Webinar Schedule
To learn more about NP Thyroid®, please visit the Acella Pharmaceuticals booth at the events listed below. Acella also invites you to attend our product theater sessions.
By clicking "Register" below, you will be redirected to the event host’s website, where you can complete your registration.
March
California Association of Nurse Practitioners
(CANP)
March 19-22 – Rancho Mirage, CA
Booth #: 107
Product Theater
Wednesday, March 19 at 6:30-8:00 pm PT
with Speaker Angela Golden, DNP, FNP-C, FAANP, FOMA
Title
Lessons in Hypothyroidism: A Look at the Unique Needs of our Patients
May
American Association of Clinical Endocrinology Annual Meeting (AACE)
May 15-17 – Orlando, FL
Booth #: 422
Product Theater
Thursday, May 15 at 10:15-11:00 am ET
with Speakers Thanh Hoang DO, FACP, FACE and Brittany Henderson, MD, ECNU
Title
Treating Hypothyroidism: A Clinical Spotlight on Desiccated Thyroid Extract
American Academy of Physician Associates
(AAPA)
May 17-21 – Denver, CO
Booth #: 1635
Product Theater
Monday May, 19 at 12:15-1:00 pm MT
with Speakers TBD
Title
TBD
June
Nurse Practitioner Associates for Continuing Education
(NPACE)
June 9-12 – Cape Cod, MA
American Association of Nurse Practitioners
(AANP)
June 17-22 – San Diego, CA
Booth #: 1817
Product Theater
Wednesday, June 18 at 11:45 am -1:00 pm PT
with Speakers Angela Mazza, DO and Barbara Dehn, NP
Title
TBD
July
Endocrine Society's Annual Meeting 2025
(ENDO)
July 12-15 – San Francisco, CA
Booth #: TBD
Product Theater
Saturday, July 12 at 12:30-1:30 pm PT
with Speakers Thanh Hoang DO, FACP, FACE, Elizabeth McAninch, MD, and David Robertson, MD
Title
The State of Desiccated Thyroid Extract in Hypothyroidism: Where We Are Now and Where We Need To Be
National Nurse Practitioner Symposium
(NNPS)
July 15-19 – Keystone, CO
Booth #: 315
Product Theater
Wednedsay, July 16
with Speaker Angela Golden, DNP, FNP-C, FAANP, FOMA
Title
Lessons in Hypothyroidism: A Look at the Unique Needs of our Patients
Florida Endocrine Association
(FEA)
July 25-27 – Orlando, FL
September
Clinical Association of California Endocrinologists
(CACE)
September 5-7 – Anaheim, CA
American Thyroid Association
(ATA)
September 10-14 – Scottsdale, AZ
Booth #: TBD
Product Theater
TBD
with Speaker TBD
Title
TBD
Nurse Practitioner Associates for Continuing Education
(NPACE)
September 22-25 – Phoenix, AZ
Texas Nurse Practitioners Annual Fall Conference
(TNP)
September 25-28 – Dallas, TX
Booth #: TBD
Product Theater
Thursday, September 25 at 12:00 pm CT
with Speaker TBD
Title
TBD
Michigan Assocation of Endocrinologists Annual Symposium
(MAE)
September 27-29 – Detroit, MI
October
Nurse Practitioners in Women's Health
(NPWH)
October 1-3 – Las Vegas, NV
Michigan Council of Nurse Practitioners Annual Conference
(MICNP)
October 10-12 – Detroit, MI
Booth #: TBD
Product Theater
TBD
with Speaker TBD
Title
TBD
New York Nurse Practitioners Association
(NYPA)
October – New York
New England Endocrine Alliance Annual Meeting
(NEEA)
Late Oct 2025
May Mid-Atlantic Society of Endocrinologists 2025 Annual Meeting (MASE)
Late Oct 2025 – Maryland
November
Nurse Practitioner Associates for Continuing Education
(NPACE)
November 2-5 – Orlando, FL
You Are About To Leave This Website
By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply.
You Are About To Leave This Website
By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply. Alora and its subsidiaries do not control the content or accuracy of third-party websites and assume no responsibility for their use.
Note that DTE products, including NP Thyroid®, have not been reviewed by the FDA for safety or efficacy.
IMPORTANT RISK INFORMATION, INCLUDING BOXED WARNING & INDICATIONS
Important Risk Information
Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
- NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
- In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
- Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
- The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
- Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
- In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
- Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
- Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
- Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
- NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.
Indications
NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.
NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid
goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the
management of thyroid cancer.
Revised 10/2023